No Data
No Data
China's Medical Device Market Value Hits $179B, 90th CMEF in Shenzhen to Feature a Plethora of Technological Products
Express News | Venus Medtech Venusp-Valve Completed First Implantation in Ide Pivotal Clinical Study in U.S.
Venus Medtech (Hangzhou) Implants First Patient With VenusP-Valve in US Clinical Study
QiMing Medical (02500): The company's self-developed PROTEUS IDE key clinical trial was recently launched and the first patient was implanted.
Kingold News | Qiming Medical (02500) announced that the company's self-developed transcatheter pulmonary valve replacement (TPVR) system, VenusP-Valve, has officially launched a critical clinical trial (PROTEUS IDE) in USA and successfully completed the first patient implantation. This marks a significant international clinical breakthrough for VenusP-Valve, following the CE MDR certification it obtained in Europe in April 2022. The start of this clinical trial means that VenusP-Valve is expected to become the leading Chinese technology approved on a global scale.
The first critical clinical patient of VENUSP-VALVE implantation in the United States IDE was successful in Qiming Medical -B (02500).
Qiming Medical -B (02500) released an announcement that the company's independently developed transcatheter pulmonary valve replacement (TPV)...
Qiming Medical-B (02500.HK): All major aspects of the Group's business operations continue to be suspended as usual
Gelonghui, May 23 | Qiming Medical-B (02500.HK) announced that the Group is mainly engaged in innovative medical device business integrating R&D, clinical development, production and commercialization. As far as the directors are aware, as of the date of this announcement, the Group's business operations were carried out as usual in all major aspects. Based on its assessment, the Board considers that the unauthorized transaction did not have any significant adverse effect on the Group's business operations. Continued suspension of trading.
No Data